CVSL

Cardio Vascular Medical Device Corp. (OTC:CVSL.OB) holds the US patent for the innovative Steerable Guidewire applicable for all PCTA  (angioplasty) procedures.The CVSL guidewire overcomes the limitations of the existing generation of guidewires.We have an opportunity to become the gold standard as the guidewire of choice for heart surgeons throughout the world, with an annual potential addressable market in excess of $500 million worldwide.

CVSL’s technology could be used in approximately 3 million procedures per year! Global demand for steerable guidewires exceeds 4.5 million annually. 

This is an ENORMOUS market! Thousands of heart surgeries are performed every day in the United States! Millions of dollars are spent on similar devices. 

With a superior patented product, CVSL has a tremendous opportunity to flourish in this rich market. 


Market The market for peripheral vascular devices is expected to grow at a CAGR of 9.1% from 2008 to 2015. In 2009, annual spending in the US market for peripheral vascular devices was estimated to be over $2.8 billion. The current estimate of the guidewire market is somewhere around $150 million. 

From 1996-2006, annual cardiovascular operations & procedures increased by 30% from 5.4 million to 7.2 million. Included in the total number are 1.3 million percutaneous coronary intervention procedures. 

Strong growth throughout the interventional cardiology market is expected to occur due to several factors. These include improved products and procedures allowing for the treatment of patients that were previously thought of as untreatable; reimbursement by insurance companies¸ resulting in more procedures taking place and higher revenues; and an increased numbers of stents used in each procedure. 

Product CVSL Solution • Improved performance. 

• Enables the neurosurgeon to reach the specified location much quicker. 

• Tip bent according to the force applied to it. 

• Made of super elastic NiTi (nickel titanium), PTFE (Teflon), coated coil and 0.15 mm wire. 

• The wire is attached to a soft tip. 

• Distral end of the coil is treated so that when the inner wire is pulled the tip buckles and bends accordingly. 

• Available in various sizes. 

• Cost efficiency for both the patient and health care provider. 

Business Strategy CVSL’s principal business plan is to develop a prototype and then manufacture and market the product and seek third party entities interested in licensing the rights to manufacture their product. 

Once they have a valid prototype, they will apply for an IRB to start conducting clinical trials, of which based on these results the Company, in conjunction with the third party manufacturers, will apply for FDA approval. 

Once FDA approval is received, the Company will seek to license the related technology to medical companies, strategic partners and / or manufacture the products for medical clinics and / or hospitals. 

Conclusion 

CVSL has a patented product that is superior to the devices currently in use. 

The unfortunate truth is that cardiovascular conditions are on the rise both domestically and abroad. CVSL is well positioned to capture a significant portion of the market for such impending procedures. 

The market is massive, and CVSL’s potential market integration could prove valuable to those who get on board with this exciting young company in the early stages. 

CVSL has traded a much higher levels in the past, at 0.012 there could be HUGE upside potential. 

http://www.marketwatch.com/investing/stock/cvsl